You're not metabolically broken. Your mitochondria just stopped talking.

That's not a metaphor — it's a mechanism. And once you understand it, the way you think about metabolic decline, insulin resistance, body composition, and aging changes completely.

I've been in clinical practice long enough to watch a predictable pattern repeat itself. Patients in their late 40s and 50s — often the same ones doing everything right on paper — come in frustrated. They're exercising consistently, eating reasonably clean, and still losing the metabolic war. Labs come back showing rising fasting insulin, creeping triglycerides, declining lean mass, and an HbA1c that was 5.1 three years ago and is now 5.7. Nothing catastrophic, but unmistakably trending in the wrong direction

When I started digging into mitochondrial-derived peptides, specifically MOTS-c, a lot of those cases started making more sense.

## What MOTS-c actually is — and why no one told you about it

MOTS-c was identified in 2015. It's a 16-amino acid peptide encoded not in your nuclear DNA, but in the mitochondrial genome itself — specifically within the 12S ribosomal RNA gene.

Here's an analogy that helps: think of your nuclear DNA as the corporate headquarters of a large company — it issues most of the directives and controls the big picture. Your mitochondria have historically been viewed as the power plants on the factory floor, just generating energy on command. What we discovered with MOTS-c is that the factory floor has its own internal messaging system, and it's been sending reports back to headquarters the entire time. MOTS-c is one of those dispatches — a mitochondrially encoded signal that travels through circulation to coordinate metabolic responses in skeletal muscle, liver, and adipose tissue.

It doesn't just stay in the cell where it was made. It functions as both a local signal and a systemic hormone, adjusting operations across your entire body based on what the mitochondria are actually experiencing on the ground.

Think of it less like a supplement and more like a firmware update your metabolism was designed to run.

## The mechanism that makes this worth paying attention to

MOTS-c exerts most of its metabolic effects through what researchers call the folate-AICAR-AMPK pathway. Here's how to think about it.

Your cells run on a constant energy accounting system. AMPK is the chief financial officer — it monitors the ratio of available energy to demand, and when reserves drop, it restructures operations accordingly. MOTS-c triggers this by disrupting the folate cycle, which causes a buildup of a compound called AICAR. AICAR mimics the low-energy signal your cells produce when ATP is running thin. AMPK reads that signal, assumes the budget is tight, and immediately shifts the organization into conservation and efficiency mode.

What that looks like metabolically: GLUT4 transporters move to the cell surface and pull glucose into skeletal muscle without requiring insulin — like opening a side door that bypasses the usual security checkpoint. Fatty acid oxidation increases. Glucose that does enter the cell gets redirected toward the pentose phosphate pathway rather than standard glycolysis — more building material, less immediate burning.

The net result is a shift from sugar-burning to fat-burning, executed more efficiently and with less oxidative waste.

Researchers have noted that this mechanism closely mirrors what Metformin does — which is why some have classified MOTS-c as a naturally occurring, mitochondrially encoded analog of first-line diabetes therapy. That framing is worth sitting with.

## Retrograde signaling: the factory floor talks back

Here's where it gets even more interesting, and where the analogy earns its keep.

Under normal resting conditions, MOTS-c stays inside the mitochondria. But under metabolic stress — fasting, exercise, caloric deficit, oxidative damage — MOTS-c does something remarkable: it leaves the mitochondria entirely and travels to the cell nucleus. Imagine the factory floor manager, after noticing the power grid is overtaxed, walking directly into the executive suite to rewrite company policy in real time.

Once inside the nucleus, MOTS-c binds to stress-responsive transcription factors — most notably Nrf2, the master regulator of the cellular antioxidant response — and activates protective gene programs. It coordinates the expression of over a hundred nuclear genes in response to signals originating in the mitochondria. That's not a peptide doing one thing. That's a peptide acting as a bilingual translator between two separate genomes that need to work in concert to keep you metabolically healthy.

When that translator goes quiet — as it does with age — the communication breakdown looks exactly like what we've come to accept as normal aging.

## Why this looks so much like exercise — because it is

One of the more striking findings in the MOTS-c literature is how consistently it reproduces the metabolic effects of high-intensity interval training.

Think of HIIT as forcing your car to redline. Your engine screams, fuel efficiency drops momentarily, but over time the stress signal triggers adaptations — better fuel economy, stronger components, more efficient combustion. MOTS-c produces the same downstream adaptations without requiring you to redline the engine. It sends the stress signal directly, skipping the physical demand that generates it naturally. Both activate AMPK, both increase GLUT4-mediated glucose uptake, both upregulate fatty acid oxidation and mitochondrial biogenesis, both shift substrate preference toward fat, and both carry net anti-inflammatory effects over time.

During actual exercise, circulating MOTS-c levels in skeletal muscle increase measurably — the peptide appears to be a natural mediator of the body's adaptation to physical stress. The exogenous version isn't tricking your body into thinking it exercised. It's delivering the same molecular signal your muscles were already designed to produce and respond to.

This creates a clinically relevant use case: patients who can't train at the intensity needed to drive these adaptations — whether due to injury, age-related deconditioning, or advanced metabolic dysfunction. I've had patients who couldn't tolerate high-intensity work at the exact moment they needed metabolic intervention the most. MOTS-c gave us another lever to pull.

## The patients who tend to benefit most

Based on what we see clinically and what the research supports, a few populations stand out.

Metabolic syndrome and insulin resistance. This is the core indication. By activating AMPK and improving glucose disposal in skeletal muscle, MOTS-c reduces the demand on the pancreas to compensate for poor insulin sensitivity. In animal models, it has reversed high-fat diet-induced insulin resistance even in already-diabetic subjects. The human data is still emerging, but the mechanism is clear and the patient response I've observed has been consistent with what the research would predict.

Sarcopenia and body composition. Think of muscle tissue as infrastructure — it's expensive to maintain, so when the body's resources are chronically strained, maintenance gets deferred. MOTS-c restores mitochondrial bioenergetic efficiency in muscle cells and suppresses myostatin, one of the primary signals that tells the body to stop building. For patients over 50 losing the lean mass battle despite adequate protein and consistent training, this is an underappreciated tool.

Aging and longevity. Here's the piece that changes the frame entirely: MOTS-c levels decline with age. Circulating MOTS-c in young healthy individuals is measurably higher than in older adults, and that decline tracks closely with the onset of the hallmarks of metabolic aging. It's the equivalent of an aging communications infrastructure — fewer signals being sent, longer delays between transmission and response, increasing miscommunication between departments. The theory gaining traction in research circles is that MOTS-c is a core component of the body's longevity program — not a drug that mimics health, but a signal that naturally declines and can be therapeutically restored.

Bone health. This is the emerging application most practitioners aren't talking about yet. MOTS-c promotes osteoblast differentiation — the bone-building crew — while simultaneously inhibiting osteoclast activity, the demolition crew. It tips the remodeling balance toward net formation by suppressing RANKL and increasing osteoprotegerin. For perimenopausal and postmenopausal patients already dealing with estrogen-driven bone loss, this is a meaningful ancillary benefit that often goes unrecognized.

## Where things stand in 2026

I want to address the regulatory piece directly, because the landscape shifted significantly in early 2026.

MOTS-c was previously included on the FDA's Category 2 "do not compound" list, which effectively prohibited licensed compounding pharmacies from preparing it. In February 2026, it was moved back to Category 1 status, meaning it can now be legally compounded pursuant to a valid physician's prescription through licensed 503A and 503B pharmacies.

This matters for two reasons. First, it means patients can now access pharmaceutical-grade, quality-controlled MOTS-c rather than navigating the unregulated research-only gray market, where contamination and dosing inaccuracy are genuine risks. Second, it signals a regulatory acknowledgment that the evidence base for compounded peptides like MOTS-c doesn't support an outright ban on access.

That said — the reclassification doesn't mean MOTS-c is without clinical considerations.

## What you need to know before starting

Because MOTS-c significantly improves insulin sensitivity and glucose uptake, hypoglycemia is a real risk — particularly in individuals who are not insulin-resistant. Here's the analogy: if your plumbing is already working efficiently and you suddenly increase the water pressure, something backs up or overflows. In a metabolically healthy person, dramatically improving glucose clearance can drive blood sugar lower than intended. That's why baseline labs — fasting glucose and HbA1c at minimum — and ongoing monitoring during therapy are not optional. They're the standard of care.

MOTS-c also interacts directly with the folate cycle, which has direct implications for anyone with an MTHFR gene variant. If you've been told you have an MTHFR polymorphism — which affects a meaningful portion of the population — this interaction needs to be evaluated before initiating therapy, not after. Your provider needs to know your genetic context before pulling this particular lever.

Dosing in clinical practice typically ranges from 5mg to 10mg per administration, given subcutaneously. Frequency ranges from three to five times per week depending on the protocol tier — whether the goal is metabolic optimization, correction of significant insulin resistance, or a longevity-maintenance approach. Cycles run eight to sixteen weeks, followed by off periods of comparable length to prevent adaptation and preserve endogenous mitochondrial signaling. Morning injection timing, ideally in a fasted state, amplifies AMPK activation by working with the body's existing low-energy state rather than against it.

Stability matters more with MOTS-c than with many other peptides. It's a fragile molecule — think of it like a delicate mechanical watch rather than a rubber ball. Heat, light, and mechanical stress all degrade it. Reconstituted vials need consistent refrigeration, away from the door and any light exposure, and should never be shaken during reconstitution.

## The reframe worth sitting with

Most of the patients I see who are struggling metabolically aren't lazy, undisciplined, or simply aging badly. They're working against a signaling system that has progressively lost its ability to adapt.

Your mitochondria aren't just power plants. They're sensors, communicators, and real-time monitors of your metabolic environment — and they've been trying to relay that information back to headquarters through peptides like MOTS-c since long before we knew how to listen. When that signal fades, the downstream consequences look a lot like what we've come to call "normal aging."

But a communication breakdown isn't the same as a broken system. Restore the signal, and you restore the conversation.

If you're going to intervene at the mitochondrial level, you want someone who understands what they're doing. The mechanism is precise, the clinical considerations are real, and the difference between a protocol that works and one that doesn't often comes down to the details.

---

Jeremiah Velasquez, FNP-BC, AGACNP-BC, is the founder of Steel City HRT & Weight Loss, a telehealth practice specializing in hormone optimization, metabolic medicine, and peptide therapy.